CoChat
Sign Up
Cited by 66Dialysis and Renal Disease ManagementDietetics, Nutrition, and EducationPharmacogenetics and Drug Metabolism

Interactions between Food and Drugs, and Nutritional Status in Renal Patients: A Narrative Review

Open access
D’Alessandro, Claudia, Benedetti, Alessia, Di Paolo, Antonello, Giannese, Domenico, Cupisti, Adamasco·2022·Nutrients
DOI 10.3390/nu14010212PMC PMC8747252
Open this paper in CoChat — free accountOpen PDF

Abstract

Drugs and food interact mutually: drugs may affect the nutritional status of the body, acting on senses, appetite, resting energy expenditure, and food intake; conversely, food or one of its components may affect bioavailability and half-life, circulating plasma concentrations of drugs resulting in an increased risk of toxicity and its adverse effects, or therapeutic failure. Therefore, the knowledge of these possible interactions is fundamental for the implementation of a nutritional treatment in the presence of a pharmacological therapy. This is the case of chronic kidney disease (CKD), for which the medication burden could be a problem, and nutritional therapy plays an important role in the patient’s treatment. The aim of this paper was to review the interactions that take place between drugs and foods that can potentially be used in renal patients, and the changes in nutritional status induced by drugs. A proper definition of the amount of food/nutrient intake, an adequate definition of the timing of meal consumption, and a proper adjustment of the drug dosing schedule may avoid these interactions, safeguarding the quality of life of the patients and guaranteeing the effectiveness of drug therapy. Hence, a close collaboration between the nephrologist, the renal dietitian, and the patient is crucial. Dietitians should consider that food may interact with drugs and that drugs may affect nutritional status, in order to provide the patient with proper dietary suggestions, and to allow the maximum effectiveness and safety of drug therapy, while preserving/correcting the nutritional status.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/nu14010212

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Picking the proper nutritional assessment method depends greatly on the setting, the objective of the study, and the characteristics of the population.

    “Given the diversity of nutritional assessment tools, picking the proper method depends greatly on the setting, the objective of the study, and the characteristics of the population [59,60].”

    From The Seven Methods for the Evaluation of Nutritional Status—ABCDEFG: Narrative Review (2026) · cites this paper as [59]

    Section 2 discusses the importance of nutritional status in patients with chronic kidney disease, while the Conclusive Remarks discuss dietetic interviews and food–drug interactions. Neither addresses how to choose a nutritional assessment method. Searches for assessment-tool selection by setting, study objective, and population characteristics found no supporting passage in our copy. (LLM, conf=0.73)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 158 · Cited by 66

Research works printed but not linked: 147

  1. [1]Hanna R.M. Ghobry L. Wassef O. Rhee C.M. Kalantar-Zadeh K. A Practical Approach to Nutrition, Protein-Energy Wasting, Sarcopenia, and Cachexia in Patients with Chronic Kidney Disease Blood Purif. 2020 49 202 211 10.1159/000504240 31851983 · DOI
  2. [2]Ackerman B.H. Kasbekar N. Disturbances of Taste and Smell Induced by Drugs Pharmacotherapy 1997 17 482 496 10.1002/j.1875-9114.1997.tb03058.x 9165552 · DOI
  3. [3]Risso D. Drayna D. Morini G. Alteration, Reduction and Taste Loss: Main Causes and Potential Implications on Dietary Habits Nutrients 2020 12 3284 10.3390/nu12113284 33120898 PMC7693910 · DOI
  4. [4]Ness-Abramof R. Apovian C.M. Drug-Induced Weight Gain Drugs Today 2005 41 547 555 10.1358/dot.2005.41.8.893630 16234878 · DOI
  5. [5]Verhaegen A.A. Van Gaal L.F. Drug-Induced Obesity and Its Metabolic Consequences: A Review with a Focus on Mechanisms and Possible Therapeutic Options J. Endocrinol. Investig. 2017 40 1165 1174 10.1007/s40618-017-0719-6 28660606 · DOI
  6. [6]Zarezadeh M. Saedisomeolia A. Shekarabi M. Khorshidi M. Emami M.R. Müller D.J. The Effect of Obesity, Macronutrients, Fasting and Nutritional Status on Drug-Metabolizing Cytochrome P450s: A Systematic Review of Current Evidence on Human Studies Eur. J. Nutr. 2021 60 2905 2921 10.1007/s00394-020-02421-y 33141242 · DOI
  7. [7]Henkin R.I. Drug-Induced Taste and Smell Disorders. Incidence, Mechanisms and Management Related Primarily to Treatment of Sensory Receptor Dysfunction Drug Saf. 1994 11 318 377 10.2165/00002018-199411050-00004 7873092 · DOI
  8. [8]Mayet A.Y. Loss of Smell (Anosmia) and Taste (Ageusia) in a Patient Treated with Pegylated Interferon Alfa and Ribavirin Curr. Ther. Res. Clin. Exp. 2007 68 271 277 10.1016/j.curtheres.2007.08.006 24683217 PMC3967281 · DOI
  9. [9]Naik B.S. Shetty N. Maben E.V.S. Drug-Induced Taste Disorders Eur. J. Intern. Med. 2010 21 240 243 10.1016/j.ejim.2010.01.017 20493431 · DOI
  10. [10]Rademacher W.M.H. Aziz Y. Hielema A. Cheung K.-C. de Lange J. Vissink A. Rozema F.R. Oral Adverse Effects of Drugs: Taste Disorders Oral Dis. 2020 26 213 223 10.1111/odi.13199 31532870 PMC6988472 · DOI
  11. [11]Toffanello E.D. Inelmen E.M. Imoscopi A. Perissinotto E. Coin A. Miotto F. Donini L.M. Cucinotta D. Barbagallo M. Manzato E. Taste Loss in Hospitalized Multimorbid Elderly Subjects Clin. Interv. Aging 2013 8 167 174 10.2147/CIA.S37477 23426191 PMC3576013 · DOI
  12. [12]Hoebel B.G. Brain Neurotransmitters in Food and Drug Reward Am. J. Clin. Nutr. 1985 42 1133 1150 10.1093/ajcn/42.5.1133 2865893 · DOI
  13. [13]Leibowitz S.F. Brain Monoamines and Peptides: Role in the Control of Eating Behavior Fed. Proc. 1986 45 1396 1403 2869977
  14. [14]Basdevant A. Neurotransmitters, Neuropeptides and Eating Behavior Diabete Metab. 1992 18 431 437 1363659
  15. [15]Aaseth J. Ellefsen S. Alehagen U. Sundfør T.M. Alexander J. Diets and Drugs for Weight Loss and Health in Obesity—An Update Biomed. Pharmacother. 2021 140 111789 10.1016/j.biopha.2021.111789 34082399 · DOI
  16. [16]Gadde K.M. Xiong G.L. Bupropion for Weight Reduction Expert Rev. Neurother. 2007 7 17 24 10.1586/14737175.7.1.17 17187492 · DOI
  17. [19]Moreira-Pais A. Ferreira R. Gil da Costa R. Platinum-Induced Muscle Wasting in Cancer Chemotherapy: Mechanisms and Potential Targets for Therapeutic Intervention Life Sci. 2018 208 1 9 10.1016/j.lfs.2018.07.010 30146014 · DOI
  18. [20]Ni J. Zhang L. Cancer Cachexia: Definition, Staging, and Emerging Treatments Cancer Manag. Res. 2020 12 5597 5605 10.2147/CMAR.S261585 32753972 PMC7358070 · DOI
  19. [21]Stohs S.J. Badmaev V. A Review of Natural Stimulant and Non-Stimulant Thermogenic Agents Phytother. Res. 2016 30 732 740 10.1002/ptr.5583 26856274 PMC5067548 · DOI
  20. [22]Marteene W. Winckel K. Hollingworth S. Kisely S. Gallagher E. Hahn M. Ebdrup B.H. Firth J. Siskind D. Strategies to Counter Antipsychotic-Associated Weight Gain in Patients with Schizophrenia Expert Opin. Drug Saf. 2019 18 1149 1160 10.1080/14740338.2019.1674809 31564170 · DOI
  21. [23]Furlong M. Deming-Halverson S. Sandler D.P. Chronic Antibiotic Use during Adulthood and Weight Change in the Sister Study PLoS ONE 2019 14 e0216959 10.1371/journal.pone.0216959 31095628 PMC6522121 · DOI
  22. [24]Domecq J.P. Prutsky G. Leppin A. Sonbol M.B. Altayar O. Undavalli C. Wang Z. Elraiyah T. Brito J.P. Mauck K.F. Clinical Review: Drugs Commonly Associated with Weight Change: A Systematic Review and Meta-Analysis J. Clin. Endocrinol. Metab. 2015 100 363 370 10.1210/jc.2014-3421 25590213 PMC5393509 · DOI
  23. [25]Fernstrom M.H. Drugs That Cause Weight Gain Obes. Res. 1995 3 (Suppl. S4) 435S 439S 10.1002/j.1550-8528.1995.tb00210.x 8697041 · DOI
  24. [26]Kalucy R.S. Drug-Induced Weight Gain Drugs 1980 19 268 278 10.2165/00003495-198019040-00002 6991239 · DOI
  25. [27]Teff K.L. Rickels M.R. Grudziak J. Fuller C. Nguyen H.-L. Rickels K. Antipsychotic-Induced Insulin Resistance and Postprandial Hormonal Dysregulation Independent of Weight Gain or Psychiatric Disease Diabetes 2013 62 3232 3240 10.2337/db13-0430 23835329 PMC3749337 · DOI · Paper page
  26. [30]Taramasso L. Bonfanti P. Ricci E. Orofino G. Squillace N. Menzaghi B. De Socio G.V. Madeddu G. Pellicanò G.F. Pagnucco L. Factors Associated with Weight Gain in People Treated with Dolutegravir Open Forum Infect. Dis. 2020 7 ofaa195 10.1093/ofid/ofaa195 32577427 PMC7295329 · DOI
  27. [31]Poulsen S.B. Fenton R.A. K+ and the Renin-Angiotensin-Aldosterone System: New Insights into Their Role in Blood Pressure Control and Hypertension Treatment J. Physiol. 2019 597 4451 4464 10.1113/JP276844 31294465 · DOI
  28. [32]Abbas A. Mirza M.M. Ganti A.K. Tendulkar K. Renal Toxicities of Targeted Therapies Target. Oncol. 2015 10 487 499 10.1007/s11523-015-0368-7 25922090 · DOI
  29. [33]Cannon-Babb M.L. Schwartz A.B. Drug-Induced Hyperkalemia Hosp. Pract. (Off. Ed.) 1986 21 99 127 99–107, 111, 114–127 2876002
  30. [34]Kovesdy C.P. Management of Hyperkalaemia in Chronic Kidney Disease Nat. Rev. Nephrol. 2014 10 653 662 10.1038/nrneph.2014.168 25223988 · DOI
  31. [35]Palmer B.F. Clegg D.J. Diagnosis and Treatment of Hyperkalemia Cleve Clin. J. Med. 2017 84 934 942 10.3949/ccjm.84a.17056 29244647 · DOI
  32. [36]Baker M. Perazella M.A. NSAIDs in CKD: Are They Safe? Am. J. Kidney Dis. 2020 76 546 557 10.1053/j.ajkd.2020.03.023 32479922 · DOI
  33. [37]Liamis G. Megapanou E. Elisaf M. Milionis H. Hyponatremia-Inducing Drugs Front. Horm. Res. 2019 52 167 177 10.1159/000493246 32097944 · DOI
  34. [38]Gröber U. Magnesium and Drugs Int. J. Mol. Sci. 2019 20 2094 10.3390/ijms20092094 PMC6539869 31035385 · DOI
  35. [39]Liamis G. Hoorn E.J. Florentin M. Milionis H. An Overview of Diagnosis and Management of Drug-Induced Hypomagnesemia Pharmacol. Res. Perspect. 2021 9 e00829 10.1002/prp2.829 34278747 PMC8287009 · DOI
  36. [40]Koyyada A. Long-Term Use of Proton Pump Inhibitors as a Risk Factor for Various Adverse Manifestations Therapie 2021 76 13 21 10.1016/j.therap.2020.06.019 32718584 · DOI
  37. [41]Liamis G. Milionis H.J. Elisaf M. A Review of Drug-Induced Hypocalcemia J. Bone Miner. Metab. 2009 27 635 642 10.1007/s00774-009-0119-x 19730969 · DOI
  38. [42]Reilly W. Ilich J. Prescription Drugs and Nutrient Depletion: How Much Is Known? Adv. Nutr. 2017 8 23 10.1093/advances/8.1.23 · DOI
  39. [43]Linder L. Tamboue C. Clements J.N. Drug-Induced Vitamin B12 Deficiency: A Focus on Proton Pump Inhibitors and Histamine-2 Antagonists J. Pharm. Pract. 2017 30 639 642 10.1177/0897190016663092 27520327 · DOI
  40. [45]Holick M.F. The Vitamin D Deficiency Pandemic: Approaches for Diagnosis, Treatment and Prevention Rev. Endocr. Metab. Disord. 2017 18 153 165 10.1007/s11154-017-9424-1 28516265 · DOI
  41. [46]Ased S. Wells J. Morrow L.E. Malesker M.A. Clinically Significant Food-Drug Interactions Consult. Pharm. 2018 33 649 657 10.4140/TCP.n.2018.649 30458907 · DOI
  42. [47]Deng J. Zhu X. Chen Z. Fan C.H. Kwan H.S. Wong C.H. Shek K.Y. Zuo Z. Lam T.N. A Review of Food-Drug Interactions on Oral Drug Absorption Drugs 2017 77 1833 1855 10.1007/s40265-017-0832-z 29076109 · DOI
  43. [48]Genser D. Food and Drug Interaction: Consequences for the Nutrition/Health Status Ann. Nutr. Metab. 2008 52 (Suppl. S1) 29 32 10.1159/000115345 18382075 · DOI
  44. [49]de Lima Toccafondo Vieira M. Huang S.-M. Botanical-Drug Interactions: A Scientific Perspective Planta Med. 2012 78 1400 1415 10.1055/s-0032-1315145 22864989 · DOI
  45. [50]Leite P.M. Martins M.A.P. Castilho R.O. Review on Mechanisms and Interactions in Concomitant Use of Herbs and Warfarin Therapy Biomed. Pharmacother. 2016 83 14 21 10.1016/j.biopha.2016.06.012 27470545 · DOI
  46. [51]Werba J.P. Misaka S. Giroli M.G. Shimomura K. Amato M. Simonelli N. Vigo L. Tremoli E. Update of Green Tea Interactions with Cardiovascular Drugs and Putative Mechanisms J. Food Drug Anal. 2018 26 S72 S77 10.1016/j.jfda.2018.01.008 29703388 PMC9326886 · DOI
  47. [52]Custodio J.M. Wu C.-Y. Benet L.Z. Predicting Drug Disposition, Absorption/Elimination/Transporter Interplay and the Role of Food on Drug Absorption Adv. Drug Deliv. Rev. 2008 60 717 733 10.1016/j.addr.2007.08.043 18199522 PMC2292816 · DOI
  48. [53]Koziolek M. Alcaro S. Augustijns P. Basit A.W. Grimm M. Hens B. Hoad C.L. Jedamzik P. Madla C.M. Maliepaard M. The Mechanisms of Pharmacokinetic Food-Drug Interactions—A Perspective from the UNGAP Group Eur. J. Pharm. Sci. 2019 134 31 59 10.1016/j.ejps.2019.04.003 30974173 · DOI
  49. [54]Palleria C. Di Paolo A. Giofrè C. Caglioti C. Leuzzi G. Siniscalchi A. De Sarro G. Gallelli L. Pharmacokinetic Drug-Drug Interaction and Their Implication in Clinical Management J. Res. Med. Sci. 2013 18 601 610 24516494 PMC3897029
  50. [55]Gu C.-H. Li H. Levons J. Lentz K. Gandhi R.B. Raghavan K. Smith R.L. Predicting Effect of Food on Extent of Drug Absorption Based on Physicochemical Properties Pharm. Res. 2007 24 1118 1130 10.1007/s11095-007-9236-1 17385020 · DOI
  51. [56]Golub A.L. Frost R.W. Betlach C.J. Gonzalez M.A. Physiologic Considerations in Drug Absorption from the Gastrointestinal Tract J. Allergy Clin. Immunol. 1986 78 689 694 10.1016/0091-6749(86)90047-3 3534051 · DOI
  52. [57]Cheng L. Wong H. Food Effects on Oral Drug Absorption: Application of Physiologically-Based Pharmacokinetic Modeling as a Predictive Tool Pharmaceutics 2020 12 672 10.3390/pharmaceutics12070672 32708881 PMC7408216 · DOI
  53. [58]Malagelada J.R. Go V.L. Summerskill W.H. Different Gastric, Pancreatic, and Biliary Responses to Solid-Liquid or Homogenized Meals Dig. Dis. Sci. 1979 24 101 110 10.1007/BF01324736 371939 · DOI
  54. [59]Roberts M.S. Magnusson B.M. Burczynski F.J. Weiss M. Enterohepatic Circulation: Physiological, Pharmacokinetic and Clinical Implications Clin. Pharmacokinet. 2002 41 751 790 10.2165/00003088-200241100-00005 12162761 · DOI
  55. [60]Honigford C.R. Aburub A. Fadda H.M. A Simulated Stomach Duodenum Model Predicting the Effect of Fluid Volume and Prandial Gastric Flow Patterns on Nifedipine Pharmacokinetics From Cosolvent-Based Capsules J. Pharm. Sci. 2019 108 288 294 10.1016/j.xphs.2018.07.023 30075162 · DOI
  56. [61]Zeller F.P. Ueda C.T. Wulf B.G. Meyers D.G. Effect of Caffeine on the Oral Absorption and Disposition of Quinidine Clin. Pharm. 1984 3 72 75 6697677
  57. [62]Yamreudeewong W. Henann N.E. Fazio A. Lower D.L. Cassidy T.G. Drug-Food Interactions in Clinical Practice J. Fam. Pract. 1995 40 376 384 7699352
  58. [63]Contin M. Martinelli P. Pharmacokinetics of Levodopa J. Neurol. 2010 257 S253 S261 10.1007/s00415-010-5728-8 21080186 · DOI
  59. [64]Semb B.K. Regional Gastric Flow Changes after Meal Stimulation Measured by the Hydrogen Clearance Technique in Conscious Cats Scand. J. Gastroenterol. 1982 17 839 842 10.3109/00365528209181102 7156879 · DOI
  60. [65]Fleisher D. Li C. Zhou Y. Pao L.H. Karim A. Drug, Meal and Formulation Interactions Influencing Drug Absorption after Oral Administration. Clinical Implications Clin. Pharmacokinet. 1999 36 233 254 10.2165/00003088-199936030-00004 10223170 · DOI
  61. [66]Harskamp-van Ginkel M.W. Hill K.D. Becker K.C. Becker K. Testoni D. Cohen-Wolkowiez M. Gonzalez D. Barrett J.S. Benjamin D.K. Siegel D.A. Drug Dosing and Pharmacokinetics in Children with Obesity: A Systematic Review JAMA Pediatr. 2015 169 678 685 10.1001/jamapediatrics.2015.132 25961828 PMC4494887 · DOI
  62. [67]Abernethy D.R. Greenblatt D.J. Drug Disposition in Obese Humans. An Update Clin. Pharmacokinet. 1986 11 199 213 10.2165/00003088-198611030-00002 3524955 · DOI
  63. [68]Sankaralingam S. Kim R.B. Padwal R.S. The Impact of Obesity on the Pharmacology of Medications Used for Cardiovascular Risk Factor Control Can. J. Cardiol. 2015 31 167 176 10.1016/j.cjca.2014.10.025 25661551 · DOI
  64. [69]Anderson B.J. Holford N.H. What Is the Best Size Predictor for Dose in the Obese Child? Paediatr. Anaesth. 2017 27 1176 1184 10.1111/pan.13272 29076211 · DOI
  65. [70]Osserman E.F. Takatsuki K. The Plasma Proteins in Liver Disease Med. Clin. N. Am. 1963 47 679 710 10.1016/S0025-7125(16)33572-6 13940565 · DOI
  66. [71]Bienenstock J. Poortmans J. Renal Clearance of 15 Plasma Proteins in Renal Disease J. Lab. Clin. Med. 1970 75 297 306 5461134
  67. [72]Toro-Ramos T. Paley C. Pi-Sunyer F.X. Gallagher D. Body Composition during Fetal Development and Infancy through the Age of 5 Years Eur. J. Clin. Nutr. 2015 69 1279 1289 10.1038/ejcn.2015.117 26242725 PMC4680980 · DOI
  68. [73]Reinders I. Visser M. Schaap L. Body Weight and Body Composition in Old Age and Their Relationship with Frailty Curr. Opin. Clin. Nutr. Metab. Care 2017 20 11 15 10.1097/MCO.0000000000000332 27749713 · DOI
  69. [74]Ronis M.J.J. Effects of Soy Containing Diet and Isoflavones on Cytochrome P450 Enzyme Expression and Activity Drug Metab. Rev. 2016 48 331 341 10.1080/03602532.2016.1206562 27440109 PMC5801744 · DOI
  70. [75]Mouly S. Lloret-Linares C. Sellier P.-O. Sene D. Bergmann J.-F. Is the Clinical Relevance of Drug-Food and Drug-Herb Interactions Limited to Grapefruit Juice and Saint-John’s Wort? Pharmacol. Res. 2017 118 82 92 10.1016/j.phrs.2016.09.038 27693910 · DOI
  71. [76]Bushra R. Aslam N. Khan A.Y. Food-Drug Interactions Oman Med. J. 2011 26 77 83 10.5001/omj.2011.21 22043389 PMC3191675 · DOI
  72. [77]Remer T. Manz F. Potential Renal Acid Load of Foods and Its Influence on Urine PH J. Am. Diet. Assoc. 1995 95 791 797 10.1016/S0002-8223(95)00219-7 7797810 · DOI
  73. [78]Choi J.H. Ko C.M. Food and Drug Interactions J. Lifestyle Med. 2017 7 1 9 10.15280/jlm.2017.7.1.1 28261555 PMC5332115 · DOI
  74. [79]Andrade C. Fruit Juice, Organic Anion Transporting Polypeptides, and Drug Interactions in Psychiatry J. Clin. Psychiatry 2014 75 e1323 e1325 10.4088/JCP.14f09572 25470100 · DOI
  75. [80]Violi F. Lip G.Y. Pignatelli P. Pastori D. Interaction between Dietary Vitamin K Intake and Anticoagulation by Vitamin K Antagonists: Is It Really True? A Systematic Review Medicine 2016 95 e2895 10.1097/MD.0000000000002895 26962786 PMC4998867 · DOI
  76. [81]Di Minno A. Frigerio B. Spadarella G. Ravani A. Sansaro D. Amato M. Kitzmiller J.P. Pepi M. Tremoli E. Baldassarre D. Old and New Oral Anticoagulants: Food, Herbal Medicines and Drug Interactions Blood Rev. 2017 31 193 203 10.1016/j.blre.2017.02.001 28196633 · DOI
  77. [82]Choi E.J. Zhang P. Kwon H. Determination of goitrogenic metabolites in the serum of male wistar rat fed structurally different glucosinolates Toxicol. Res. 2014 30 109 116 10.5487/TR.2014.30.2.109 25071920 PMC4112061 · DOI
  78. [83]Felker P. Bunch R. Leung A.M. Concentrations of thiocyanate and goitrin in human plasma, their precursor concentrations in brassica vegetables, andassociated potential risk for hypothyroidism Nutr Rev. 2016 74 248 258 10.1093/nutrit/nuv110 26946249 PMC4892312 · DOI
  79. [84]Otun J. Sahebkar A. Östlundh L. Atkin S.L. Sathyapalan T. Systematic Review and Meta-Analysis on the Effect of Soy on Thyroid Function Sci. Rep. 2019 9 3964 10.1038/s41598-019-40647-x 30850697 PMC6408586 · DOI · Paper page
  80. [85]Kiani J. Imam S.Z. Medicinal Importance of Grapefruit Juice and Its Interaction with Various Drugs Nutr. J. 2007 6 33 10.1186/1475-2891-6-33 17971226 PMC2147024 · DOI
  81. [86]Bailey D.G. Malcolm J. Arnold O. Spence J.D. Grapefruit Juice-Drug Interactions Br. J. Clin. Pharmacol. 1998 46 101 110 10.1046/j.1365-2125.1998.00764.x 9723817 PMC1873672 · DOI
  82. [87]Greenblatt D.J. Analysis of Drug Interactions Involving Fruit Beverages and Organic Anion-Transporting Polypeptides J. Clin. Pharmacol. 2009 49 1403 1407 10.1177/0091270009342251 19789373 · DOI
  83. [88]Egashira K. Ohtani H. Itoh S. Koyabu N. Tsujimoto M. Murakami H. Sawada Y. Inhibitory Effects of Pomelo on the Metabolism of Tacrolimus and the Activities of CYP3A4 and P-Glycoprotein Drug Metab. Dispos. 2004 32 828 833 10.1124/dmd.32.8.828 15258108 · DOI
  84. [89]Shirasaka Y. Shichiri M. Mori T. Nakanishi T. Tamai I. Major Active Components in Grapefruit, Orange, and Apple Juices Responsible for OATP2B1-Mediated Drug Interactions J. Pharm. Sci. 2013 102 3418 3426 10.1002/jps.23653 23794501 · DOI
  85. [90]Bailey D.G. Fruit Juice Inhibition of Uptake Transport: A New Type of Food-Drug Interaction Br. J. Clin. Pharmacol. 2010 70 645 655 10.1111/j.1365-2125.2010.03722.x 21039758 PMC2997304 · DOI
  86. [91]Hanley M.J. Masse G. Harmatz J.S. Cancalon P.F. Dolnikowski G.G. Court M.H. Greenblatt D.J. Effect of Blueberry Juice on Clearance of Buspirone and Flurbiprofen in Human Volunteers Br. J. Clin. Pharmacol. 2013 75 1041 1052 10.1111/j.1365-2125.2012.04450.x 22943633 PMC3612722 · DOI
  87. [92]Srinivas N.R. Is Pomegranate Juice a Potential Perpetrator of Clinical Drug-Drug Interactions? Review of the in Vitro, Preclinical and Clinical Evidence Eur. J. Drug Metab. Pharmacokinet. 2013 38 223 229 10.1007/s13318-013-0137-x 23673492 · DOI
  88. [93]Chen M. Zhou S.Y. Fabriaga E. Zhang P.H. Zhou Q. Food-drug interactions precipitated by fruit juices other than grapefruit juice: An update review J. Food Drug Anal. 2018 26 S61 S71 10.1016/j.jfda.2018.01.009 29703387 PMC9326888 · DOI
  89. [94]Tsujimoto M. Agawa C. Ueda S. Yamane T. Kitayama H. Terao A. Fukuda T. Minegaki T. Nishiguchi K. Inhibitory Effects of Juices Prepared from Individual Vegetables on CYP3A4 Activity in Recombinant CYP3A4 and LS180 Cells Biol. Pharm. Bull. 2017 40 1561 1565 10.1248/bpb.b17-00116 28867739 · DOI
  90. [95]Guo X. Mei N. Aloe Vera: A Review of Toxicity and Adverse Clinical Effects J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev. 2016 34 77 96 10.1080/10590501.2016.1166826 26986231 PMC6349368 · DOI
  91. [96]Ali M.Y. Sina A.A. Khandker S.S. Neesa L. Tanvir E.M. Kabir A. Khalil M.I. Gan S.H. Nutritional Composition and Bioactive Compounds in Tomatoes and Their Impact on Human Health and Disease: A Review Foods 2020 26 45 10.3390/foods10010045 33375293 PMC7823427 · DOI
  92. [97]Sunaga K. Ohkawa K. Nakamura K. Ohkubo A. Harada S. Tsuda T. Mechanism-Based Inhibition of Recombinant Human Cytochrome P450 3A4 by Tomato Juice Extract Biol. Pharm. Bull. 2012 35 329 334 10.1248/bpb.35.329 22382318 · DOI
  93. [98]Briguglio M. Hrelia S. Malaguti M. Serpe L. Canaparo R. Dell’Osso B. Galentino R. De Michele S. Dina C.Z. Porta M. Food Bioactive Compounds and Their Interference in Drug Pharmacokinetic/Pharmacodynamic Profiles Pharmaceutics 2018 10 277 10.3390/pharmaceutics10040277 30558213 PMC6321138 · DOI
  94. [99]Awortwe C. Makiwane M. Reuter H. Muller C. Louw J. Rosenkranz B. Critical Evaluation of Causality Assessment of Herb-Drug Interactions in Patients Br. J. Clin. Pharmacol. 2018 84 679 693 10.1111/bcp.13490 29363155 PMC5867089 · DOI
  95. [100]Guengerich P.F. Avadhani N.G. Roles of Cytochrome P450 in Metabolism of Ethanol and Carcinogens Adv. Exp. Med. Biol. 2018 1032 15 35 10.1007/978-3-319-98788-0_2 30362088 PMC6371814 · DOI
  96. [102]Detampel P. Beck M. Krähenbühl S. Huwyler J. Drug interaction potential of resveratrol Drug Metab. Rev. 2012 44 253 265 10.3109/03602532.2012.700715 22788578 · DOI
  97. [103]Mutschler J. Grosshans M. Soyka M. Rösner S. Current Findings and Mechanisms of Action of Disulfiram in the Treatment of Alcohol Dependence Pharmacopsychiatry 2016 49 137 141 10.1055/s-0042-103592 26987743 · DOI
  98. [105]Albassam A.A. Markowitz J.S. An Appraisal of Drug-Drug Interactions with Green Tea (Camellia sinensis) Planta Med. 2017 83 496 508 10.1055/s-0043-100934 28118673 · DOI
  99. [106]Abe O. Ono T. Sato H. Müller F. Ogata H. Miura I. Shikama Y. Yabe H. Onoue S. Fromm M.F. Role of (-)-epigallocatechin gallate in the pharmacokinetic interaction between nadolol and green tea in healthy volunteers Eur. J. Clin. Pharmacol. 2018 74 775 783 10.1007/s00228-018-2436-2 29480324 · DOI
  100. [107]Raaska K. Raitasuo V. Laitila J. Neuvonen P.J. Effect of Caffeine-Containing versus Decaffeinated Coffee on Serum Clozapine Concentrations in Hospitalised Patients Basic Clin. Pharmacol. Toxicol. 2004 94 13 18 10.1111/j.1742-7843.2004.pto940104.x 14725610 · DOI
  101. [108]Wright K.P. Myers B.L. Plenzler S.C. Drake C.L. Badia P. Acute Effects of Bright Light and Caffeine on Nighttime Melatonin and Temperature Levels in Women Taking and Not Taking Oral Contraceptives Brain Res. 2000 873 310 317 10.1016/S0006-8993(00)02557-9 10930561 · DOI
  102. [110]Choi S.O. Jung S.-H. Um S.-Y. Jung S.-J. Kim J.-I. Chung S.Y. Food-Effect Bioavailability and Fed Bioequivalence Studies J. Korean Pharm. Sci. 2004 34 223 228 10.4333/KPS.2004.34.3.223 · DOI
  103. [111]Koziolek M. Carrière F. Porter C.J.H. Lipids in the Stomach—Implications for the Evaluation of Food Effects on Oral Drug Absorption Pharm. Res. 2018 35 55 10.1007/s11095-017-2289-x 29423732 · DOI
  104. [112]González Canga A. Fernández Martínez N. Sahagún Prieto A.M. García Vieitez J.J. Díez Liébana M.J. Díez Láiz R. Sierra Vega M. Dietary Fiber and Its Interaction with Drugs Nutr. Hosp. 2010 25 535 539 20694287
  105. [113]Betz J.M. Rimmer C.A. Saldanha L.G. Phillips M.M. Andrews K.W. Wise S.A. Wood L.J. Kuszak A.J. Gusev P.A. Pehrsson P.R. Challenges in Developing Analytically Validated Laboratory-Derived Dietary Supplement Databases J. Nutr. 2018 1 1406S 1412S 10.1093/jn/nxy134 PMC6857616 31505676 · DOI
  106. [114]Ronis M.J.J. Pedersen K.B. Watt J. Adverse Effects of Nutraceuticals and Dietary Supplements Annu. Rev. Pharmacol. Toxicol. 2018 58 583 601 10.1146/annurev-pharmtox-010617-052844 28992429 PMC6380172 · DOI
  107. [115]Tirona R.G. Bailey D.G. Herbal Product-Drug Interactions Mediated by Induction Br. J. Clin. Pharmacol. 2006 61 677 681 10.1111/j.1365-2125.2006.02684.x 16722828 PMC1885112 · DOI
  108. [116]Wierzejska R.E. Dietary Supplements-For Whom? The Current State of Knowledge about the Health Effects of Selected Supplement Use Int. J. Environ. Res. Public Health 2021 24 8897 10.3390/ijerph18178897 PMC8431076 34501487 · DOI
  109. [117]Chang T.K.H. Activation of Pregnane X Receptor (PXR) and Constitutive Androstane Receptor (CAR) by Herbal Medicines AAPS J. 2009 11 590 601 10.1208/s12248-009-9135-y 19688601 PMC2758128 · DOI
  110. [118]Na D.H. Ji H.Y. Park E.J. Kim M.S. Liu K.H. Lee H.S. Evaluation of metabolism-mediated herb–drug interactions Arch. Pharm. Res. 2011 34 1829 1842 10.1007/s12272-011-1105-0 22139684 · DOI
  111. [119]Hermann R. von Richter O. Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions Planta Med. 2012 78 1458 1477 10.1055/s-0032-1315117 22855269 · DOI
  112. [121]Borrelli F. Izzo A.A. Herb-Drug Interactions with St John’s Wort (Hypericum Perforatum): An Update on Clinical Observations AAPS J. 2009 11 710 727 10.1208/s12248-009-9146-8 19859815 PMC2782080 · DOI
  113. [122]Unger M. Pharmacokinetic Drug Interactions Involving Ginkgo Biloba Drug Metab. Rev. 2013 45 353 385 10.3109/03602532.2013.815200 23865865 · DOI
  114. [123]Crawford C. Boyd C. Avula B. Wang Y.H. Khan I.A. Deuster P.A. A Public Health Issue: Dietary Supplements Promoted for Brain Health and Cognitive Performance J. Altern. Complement. Med. 2020 26 265 272 10.1089/acm.2019.0447 32119795 PMC7153641 · DOI
  115. [124]Tan M.S. Yu J.T. Tan C.C. Wang H.F. Meng X.F. Wang C. Jiang T. Zhu X.C. Tan L. Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: A systematic review and meta-analysis J. Alzheimers Dis. 2015 43 589 603 10.3233/JAD-140837 25114079 · DOI
  116. [125]Roland P.D. Nergård C.S. Ginkgo biloba—Effekt, bivirkninger og interaksjoner [Ginkgo biloba—Effect, adverse events and drug interaction] Tidsskr Nor Laegeforen 2012 30 956 959 Erratum in Tidsskr Nor Laegeforen 2012, 132, 1319 10.4045/tidsskr.11.0780 22562327 · DOI
  117. [126]Ke J. Li M.T. Huo Y.J. Cheng Y.Q. Guo S.F. Wu Y. Zhang L. Ma J. Liu A.J. Han Y. The Synergistic Effect of Ginkgo biloba Extract 50 and Aspirin Against Platelet Aggregation Drug Des Devel Ther. 2021 14 3543 3560 10.2147/DDDT.S318515 PMC8375244 34429584 · DOI
  118. [127]Williams B. Watanabe C.M. Schultz P.G. Rimbach G. Krucker T. Age-related effects of Ginkgo biloba extract on synaptic plasticity and excitability Neurobiol. Aging 2004 25 955 962 10.1016/j.neurobiolaging.2003.10.008 15212849 · DOI
  119. [128]Kehr J. Yoshitake S. Ijiri S. Koch E. Noldner M. Yoshitake T. Ginkgo biloba leaf extract (EGb 761(R)) and its specific acylated flavonol constituents increase dopamine and acetylcholine levels in the rat medial prefrontal cortex: Possible implications for the cognitive enhancing properties of EGb 761(R) Int. Psychogeriatr. 2012 24 S25 S34 10.1017/S1041610212000567 22784425 · DOI
  120. [129]Yoshitake T. Yoshitake S. Kehr J. The Ginkgo biloba extract EGb 761(R) and its main constituent flavonoids and ginkgolides increase extracellular dopamine levels in the rat prefrontal cortex Br. J. Pharmacol. 2010 159 659 668 10.1111/j.1476-5381.2009.00580.x 20105177 PMC2828029 · DOI
  121. [130]Fugh-Berman A. Herb-Drug Interactions Lancet 2000 355 134 138 10.1016/S0140-6736(99)06457-0 10675182 · DOI
  122. [131]Posadzki P. Watson L.K. Ernst E. Adverse effects of herbal medicines: An overview of systematic reviews Clin. Med. 2013 13 7 12 10.7861/clinmedicine.13-1-7 PMC5873713 23472485 · DOI
  123. [132]Izzo A.A. Ernst E. Interactions between herbal medicines and prescribed drugs: A systematic review Drugs 2001 61 2163 2175 10.2165/00003495-200161150-00002 11772128 · DOI
  124. [133]Kwon Y.J. Son D.H. Chung T.H. Lee Y.J. A Review of the Pharmacological Efficacy and Safety of Licorice Root from Corroborative Clinical Trial Findings J. Med. Food 2020 23 12 20 10.1089/jmf.2019.4459 31874059 · DOI
  125. [134]Makino T. Okajima K. Uebayashi R. Ohtake N. Inoue K. Mizukami H. 3-Monoglucuronyl-glycyrrhretinic acid is a substrate of organic anion transporters expressed in tubular epithelial cells and plays important roles in licorice-induced pseudoaldosteronism by inhibiting 11β-hydroxysteroid dehydrogenase 2 J. Pharmacol. Exp. Ther. 2012 342 297 304 10.1124/jpet.111.190009 22543032 · DOI
  126. [136]Oh M.R. Park S.H. Kim S.Y. Back H.I. Kim M.G. Jeon J.Y. Ha K.C. Na W.T. Cha Y.S. Park B.H. Postprandial glucose-lowering effects of fermented red ginseng in subjects with impaired fasting glucose or type 2 diabetes: A randomized, double-blind, placebo-controlled clinical trial BMC Complement. Altern. Med. 2014 14 237 10.1186/1472-6882-14-237 25015735 PMC4227112 · DOI
  127. [137]Teng C.M. Kuo S.C. Ko F.N. Lee J.C. Lee L.G. Chen S.C. Huang T.F. Antiplatelet actions of panaxynol and ginsenosides isolated from ginseng Biochim. Biophys. Acta 1989 990 315 320 10.1016/S0304-4165(89)80051-0 2923911 · DOI
  128. [138]Ramanathan M.R. Penzak S.R. Pharmacokinetic Drug Interactions with Panax Ginseng Eur. J. Drug Metab. Pharmacokinet. 2017 42 545 557 10.1007/s13318-016-0387-5 27864798 · DOI
  129. [139]Malati C.Y. Robertson S.M. Hunt J.D. Chairez C. Alfaro R.M. Kovacs J.A. Penzak S.R. Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants J. Clin. Pharmacol. 2012 52 932 939 10.1177/0091270011407194 21646440 PMC3523324 · DOI
  130. [140]Choi M.K. Song I.S. Interactions of ginseng with therapeutic drugs Arch. Pharm. Res. 2019 42 862 878 10.1007/s12272-019-01184-3 31493264 · DOI
  131. [141]Xin H.W. Wu X.C. Li Q. Yu A.R. Zhu M. Shen Y. Su D. Xiong L. Effects of Schisandra sphenanthera extract on the pharmacokinetics of tacrolimus in healthy volunteers Br. J. Clin. Pharmacol. 2007 64 469 475 10.1111/j.1365-2125.2007.02922.x 17506780 PMC2048562 · DOI
  132. [142]Seong S.J. Kang W.Y. Heo J.K. Jo J. Choi W.G. Liu K.H. Lee S. Choi M.K. Han Y.H. Lee H.S. A comprehensive in vivo and in vitro assessment of the drug interaction potential of red ginseng Clin. Ther. 2018 40 1322 1337 10.1016/j.clinthera.2018.06.017 30078466 · DOI
  133. [143]Bhardwaj R.K. Glaeser H. Becquemont L. Klotz U. Gupta S.K. Fromm M.F. Piperine, a Major Constituent of Black Pepper, Inhibits Human P-Glycoprotein and CYP3A4 J. Pharmacol. Exp. Ther. 2002 302 645 650 10.1124/jpet.102.034728 12130727 · DOI
  134. [144]Han H.-K. The Effects of Black Pepper on the Intestinal Absorption and Hepatic Metabolism of Drugs Expert Opin. Drug Metab. Toxicol. 2011 7 721 729 10.1517/17425255.2011.570332 21434835 · DOI
  135. [145]Gurley B.J. Fifer E.K. Gardner Z. Pharmacokinetic herb-drug interactions (part 2): Drug interactions involving popular botanical dietary supplements and their clinical relevance Planta Med. 2012 78 1490 1514 10.1055/s-0031-1298331 22565299 · DOI · Paper page
  136. [146]Bahramsoltani R. Rahimi R. Farzaei M.H. Pharmacokinetic Interactions of Curcuminoids with Conventional Drugs: A Review J. Ethnopharmacol. 2017 209 1 12 10.1016/j.jep.2017.07.022 28734960 · DOI
  137. [147]Unlu A. Nayir E. Dogukan Kalenderoglu M. Kirca O. Ozdogan M. Curcumin (Turmeric) and cancer J. BUON 2016 21 1050 1060 27837604
  138. [148]Soleimani V. Sahebkar A. Hosseinzadeh H. Turmeric (Curcuma longa) and its major constituent (curcumin) as nontoxic and safe substances: Review Phytother. Res. 2018 32 985 995 10.1002/ptr.6054 29480523 · DOI
  139. [149]Gupta S.C. Sung B. Kim J.H. Prasad S. Li S. Aggarwal B.B. Multitargeting by turmeric, the golden spice: From kitchen to clinic Mol. Nutr. Food Res. 2013 57 1510 1528 10.1002/mnfr.201100741 22887802 · DOI
  140. [150]Xu W. Choi H.-K. Huang L. State of Panax Ginseng Research: A Global Analysis Molecules 2017 22 1518 10.3390/molecules22091518 28892002 PMC6151615 · DOI
  141. [151]Baskaran P. Covington K. Bennis J. Mohandass A. Lehmann T. Thyagarajan B. Binding Efficacy and Thermogenic Efficiency of Pungent and Nonpungent Analogs of Capsaicin Molecules 2018 23 3198 10.3390/molecules23123198 PMC6321193 30518154 · DOI
  142. [152]Varghese S. Kubatka P. Rodrigo L. Gazdikova K. Caprnda M. Fedotova J. Zulli A. Kruzliak P. Büsselber D. Chili pepper as a body weight-loss food Int. J. Food Sci. Nutr. 2017 68 392 401 10.1080/09637486.2016.1258044 27899046 · DOI
  143. [153]Fattori V. Hohmann M.S. Rossaneis A.C. Pinho-Ribeiro F.A. Verri W.A. Capsaicin: Current Understanding of Its Mechanisms and Therapy of Pain and Other Pre-Clinical and Clinical Uses Molecules 2016 28 844 10.3390/molecules21070844 27367653 PMC6273101 · DOI
  144. [154]Frydas S. Varvara G. Murmura G. Saggini A. Caraffa A. Antinolfi P. Tete’ S. Tripodi D. Conti F. Cianchetti E. Impact of capsaicin on mast cell inflammation Int. J. Immunopathol. Pharmacol. 2013 26 597 600 10.1177/039463201302600303 24067456 · DOI
  145. [155]Espiritu M.J. Chen J. Yadav J. Larkin M. Pelletier R.D. Chan J.M. Gc J.B. Natesan S. Harrelson J.P. Mechanisms of Herb-Drug Interactions Involving Cinnamon and CYP2A6: Focus on Time-Dependent Inhibition by Cinnamaldehyde and 2-Methoxycinnamaldehyde Drug Metab. Dispos. 2020 48 1028 1043 10.1124/dmd.120.000087 32788161 PMC7543486 · DOI
  146. [156]Singh N. Rao A.S. Nandal A. Kumar S. Yadav S.S. Ganaie S.A. Narasimhan B. Phytochemical and pharmacological review of Cinnamomum verum J. Presl-a versatile spice used in food and nutrition Food Chem. 2021 15 127773 10.1016/j.foodchem.2020.127773 32829297 · DOI
  147. [157]Seibel R. Schneider R.H. Gottlieb M.G.V. Effects of Spices (Saffron, Rosemary, Cinnamon, Turmeric and Ginger) in Alzheimer’s Disease Curr. Alzheimer Res. 2021 18 347 357 10.2174/1567205018666210716122034 34279199 · DOI

Authors
D’Alessandro, C., Benedetti, A., Di Paolo, A., Giannese, D., & Cupisti, A.
Affiliations
  • University of Pisa (IT)
  • Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 56, 56126 Pisa, Italy
Corresponding author
Cupisti, Adamasco
ORCID
Venue
Nutrients
Publisher
MDPI AG
Published
2022-01-04
Volume
14
Issue
1
Pages
212
ISSN
2072-6643 (ISSN-L)
DOI
10.3390/nu14010212
PMC
PMC8747252
OpenAlex
W4205739485
Cited by
66
References
158
Citations by year
2026: 16 · 2025: 24 · 2024: 15 · 2023: 8 · 2022: 3
FWCI
1.88
Type
journal article
Language
en
Open access
Licence
Locations
  • Nutrients (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
  • Health Sciences › Health Professions › Health Information Management › Dietetics, Nutrition, and Education
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Keywords
food-drug interactions, nutritional status, chronic kidney disease, renal patients, nutritional therapy, drug bioavailability, drug toxicity, meal timing, dose adjustment, renal dietitians
MeSH terms
Appetite, Biological Availability, Diet, Energy Metabolism, Food, Humans, Kidney Diseases, Nutritional Status, Pharmacokinetics, Quality of Life, Food-Drug Interactions, Nutrition Therapy, Nutritionists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review